Lyn Rees - Novacyt CEO Director

ALNOV Stock  EUR 0.41  0.01  2.38%   

CEO

Lyn Rees is CEO Director of Novacyt
Age 53
Address 131 Boulevard Carnot, Le Vésinet, France, 78110
Phone33 1 39 46 51 04
Webhttps://www.novacyt.com

Novacyt Management Efficiency

The company has return on total asset (ROA) of (0.111) % which means that it has lost $0.111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5122) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt's management efficiency ratios could be used to measure how well Novacyt manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/06/2026, Return On Tangible Assets is likely to drop to -0.78. In addition to that, Return On Capital Employed is likely to grow to -0.5. At this time, Novacyt's Total Current Liabilities is relatively stable compared to the past year. As of 02/06/2026, Non Current Liabilities Total is likely to grow to about 20 M, while Liabilities And Stockholders Equity is likely to drop slightly above 72 M.
Novacyt has accumulated 11.88 M in total debt with debt to equity ratio (D/E) of 26.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novacyt has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novacyt until it has trouble settling it off, either with new capital or with free cash flow. So, Novacyt's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novacyt sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novacyt to invest in growth at high rates of return. When we think about Novacyt's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

CEO Age

Ludovic LastennetImplanet SA
N/A
Martin DeterreTheradiag SA
N/A
Mario CrovettoIkonisys SA
72
Laurent CassedanneAdvicenne
58
Nicolas TrouchePoxel SA
N/A
Alexandre LoiseauMauna Kea Technologies
N/A
Gavin SpencerNicOx SA
57
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 111 people. Novacyt (ALNOV) is traded on Euronext Paris in France and employs 234 people. Novacyt is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Novacyt Leadership Team

Elected by the shareholders, the Novacyt's board of directors comprises two types of representatives: Novacyt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt's management team and ensure that shareholders' interests are well served. Novacyt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Coyne, Chief Officer
Wendy Cox, Director HR
Steve Gibson, Member of the Executive Team, Group Financial Controller
David Franks, Chief Officer
Grald Ulrich, Chief Devel
Lyn Rees, CEO Director
James McCarthy, Acting CFO
Joanne Mason, Chief Director
Wendy Karban, Member of the Executive Team, Group Human Resource Manager
Bryan Close, Chief Officer
Paul Oladimeji, Group RD

Novacyt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novacyt a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novacyt Stock Analysis

When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.